These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37802566)

  • 1. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
    Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
    Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
    Julg B; Stephenson KE; Wagh K; Tan SC; Zash R; Walsh S; Ansel J; Kanjilal D; Nkolola J; Walker-Sperling VEK; Ophel J; Yanosick K; Borducchi EN; Maxfield L; Abbink P; Peter L; Yates NL; Wesley MS; Hassell T; Gelderblom HC; deCamp A; Mayer BT; Sato A; Gerber MW; Giorgi EE; Gama L; Koup RA; Mascola JR; Monczor A; Lupo S; Rolle CP; Arduino R; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
    Nat Med; 2022 Jun; 28(6):1288-1296. PubMed ID: 35551291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.
    Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Anderson MA; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
    PLoS Med; 2024 Jun; 21(6):e1004329. PubMed ID: 38913710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.
    Gaudinski MR; Houser KV; Doria-Rose NA; Chen GL; Rothwell RSS; Berkowitz N; Costner P; Holman LA; Gordon IJ; Hendel CS; Kaltovich F; Conan-Cibotti M; Gomez Lorenzo M; Carter C; Sitar S; Carlton K; Gall J; Laurencot C; Lin BC; Bailer RT; McDermott AB; Ko SY; Pegu A; Kwon YD; Kwong PD; Namboodiri AM; Pandey JP; Schwartz R; Arnold F; Hu Z; Zhang L; Huang Y; Koup RA; Capparelli EV; Graham BS; Mascola JR; Ledgerwood JE;
    Lancet HIV; 2019 Oct; 6(10):e667-e679. PubMed ID: 31473167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087).
    Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
    medRxiv; 2024 Jan; ():. PubMed ID: 38260276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial.
    Mahomed S; Garrett N; Karim QA; Zuma NY; Capparelli E; Baxter C; Gengiah T; Archary D; Samsunder N; Doria-Rose N; Moore P; Williamson C; Barouch DH; Fast PE; Pozzetto B; Hankins C; Carlton K; Ledgerwood J; Morris L; Mascola J; Abdool Karim S
    BMJ Open; 2020 Nov; 10(11):e042247. PubMed ID: 33243815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
    Mkhize NN; Yssel AEJ; Kaldine H; van Dorsten RT; Woodward Davis AS; Beaume N; Matten D; Lambson B; Modise T; Kgagudi P; York T; Westfall DH; Giorgi EE; Korber B; Anthony C; Mapengo RE; Bekker V; Domin E; Eaton A; Deng W; DeCamp A; Huang Y; Gilbert PB; Gwashu-Nyangiwe A; Thebus R; Ndabambi N; Mielke D; Mgodi N; Karuna S; Edupuganti S; Seaman MS; Corey L; Cohen MS; Hural J; McElrath MJ; Mullins JI; Montefiori D; Moore PL; Williamson C; Morris L
    PLoS Pathog; 2023 Jun; 19(6):e1011469. PubMed ID: 37384759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention.
    Mahomed S; Garrett N; Capparelli EV; Osman F; Harkoo I; Yende-Zuma N; Gengiah TN; Archary D; Samsunder N; Baxter C; Mkhize NN; Modise T; Carlton K; McDermott A; Moore PL; Karim QA; Barouch DH; Fast PE; Mascola JR; Ledgerwood JE; Morris L; Abdool Karim SS
    J Infect Dis; 2022 Aug; 226(3):510-520. PubMed ID: 35134995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS.
    Wesley MS; Chiong KT; Seaton KE; Arocena CA; Sawant S; Hare J; Hernandez K; Rojas M; Heptinstall J; Beaumont D; Crisafi K; Nkolola J; Barouch DH; Sarzotti-Kelsoe M; Tomaras GD; Yates NL
    Front Immunol; 2021; 12():709994. PubMed ID: 34504492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial.
    Mahomed S; Garrett N; Capparelli E; Baxter C; Zuma NY; Gengiah T; Archary D; Moore P; Samsunder N; Barouch DH; Mascola J; Ledgerwood J; Morris L; Abdool Karim S
    BMJ Open; 2019 Jul; 9(7):e030283. PubMed ID: 31272988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial.
    Mahomed S; Garrett N; Capparelli EV; Osman F; Mkhize NN; Harkoo I; Gengiah TN; Mansoor LE; Baxter C; Archary D; Yende-Zuma N; Samsunder N; Carlton K; Narpala S; McDermott AB; Doria-Rose NA; Moore PL; Morris L; Abdool Karim Q; Mascola JR; Abdool Karim SS
    Lancet HIV; 2023 Apr; 10(4):e230-e243. PubMed ID: 37001964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.
    Awan SF; Pegu A; Strom L; Carter CA; Hendel CS; Holman LA; Costner PJ; Trofymenko O; Dyer R; Gordon IJ; Rothwell RSS; Hickman SP; Conan-Cibotti M; Doria-Rose NA; Lin BC; O'Connell S; Narpala SR; Almasri CG; Liu C; Ko S; Kwon YD; Namboodiri AM; Pandey JP; Arnold FJ; Carlton K; Gall JG; Kwong PD; Capparelli EV; Bailer RT; McDermott AB; Chen GL; Koup RA; Mascola JR; Coates EE; Ledgerwood JE; Gaudinski MR;
    JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38587079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.
    Julg B; Walker-Sperling VEK; Wagh K; Aid M; Stephenson KE; Zash R; Liu J; Nkolola JP; Hoyt A; Castro M; Serebryannyy L; Yanosick K; Speidel T; Borducchi EN; Murzda T; Maxfield L; Arduino R; McDermott AB; Gama L; Giorgi EE; Koup RA; Seaman MS; Rolle CP; DeJesus E; Li W; Korber B; Barouch DH
    Nat Med; 2024 Sep; ():. PubMed ID: 39266747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial.
    Mahomed S; Garrett N; Potloane D; Sikazwe IT; Capparelli E; Harkoo I; Gengiah TN; Zuma NY; Osman F; Mansoor L; Archary D; Myeni N; Radebe P; Samsunder N; Doria-Rose N; Carlton K; Gama L; Koup RA; Narpala S; Serebryannyy L; Moore P; Williamson C; Pozzetto B; Hankins C; Morris L; Karim QA; Abdool Karim S
    BMJ Open; 2023 Aug; 13(8):e076843. PubMed ID: 37640457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial.
    Goga A; Ramraj T; Naidoo L; Daniels B; Matlou M; Chetty T; Dassaye R; Ngandu NK; Galli L; Reddy T; Seocharan I; Ndlangamandla Q; September Q; Ngcobo N; Reddy M; Cafun-Naidoo T; Woeber K; Jeenarain N; Imamdin R; Maharajh K; Ramjeth A; Bhengu T; Clarence E; Van de Perre P; Tylleskär T; Nagot N; Moles JP; Moore PL; Mkhize NN; Gama L; Dispinseri S; Biswas P; Scarlatti G;
    BMC Infect Dis; 2024 Jul; 24(1):712. PubMed ID: 39033300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
    Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
    PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
    Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
    J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities.
    Mullick R; Sutar J; Hingankar N; Deshpande S; Thakar M; Sahay S; Ringe RP; Mukhopadhyay S; Patil A; Bichare S; Murugavel KG; Srikrishnan AK; Goyal R; Sok D; Bhattacharya J
    Retrovirology; 2021 May; 18(1):12. PubMed ID: 33990195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
    Casazza JP; Cale EM; Narpala S; Yamshchikov GV; Coates EE; Hendel CS; Novik L; Holman LA; Widge AT; Apte P; Gordon I; Gaudinski MR; Conan-Cibotti M; Lin BC; Nason MC; Trofymenko O; Telscher S; Plummer SH; Wycuff D; Adams WC; Pandey JP; McDermott A; Roederer M; Sukienik AN; O'Dell S; Gall JG; Flach B; Terry TL; Choe M; Shi W; Chen X; Kaltovich F; Saunders KO; Stein JA; Doria-Rose NA; Schwartz RM; Balazs AB; Baltimore D; Nabel GJ; Koup RA; Graham BS; Ledgerwood JE; Mascola JR;
    Nat Med; 2022 May; 28(5):1022-1030. PubMed ID: 35411076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.